Table 1

Demographics at baseline

UST (n=426)TNFi (n=442)
Age, years (95% CI)51.2 (12.47) (50.0 to 52.3)48.5 (12.59) (47.3 to 49.7)
Sex—male, n (%) (95% CI)183 (43.0) (38.2 to 47.8)202 (45.7) (41.0 to 50.5)
Disease duration since initial diagnosis, years (95% CI)7.5 (8.1) (6.8 to 8.3)6.2 (6.6) (5.6 to 6.8)
BMI, kg/m2 (95% CI)28.6 (6.3) (27.9 to 29.3)27.7 (5.0) (27.2 to 28.3)
csDMARD exposure, n (%) (95% CI)
 Previous exposure376 (88.3) (84.8 to 91.2)411 (93.0) (84.8 to 91.2)
 Ongoing exposure at baseline167 (39.2) (34.5 to 44.0)241 (54.5) (49.8 to 59.2)
Methotrexate exposure ongoing at baseline, n (%) (95% CI)127 (29.8) (25.5 to 34.4)187 (42.3) (37.7 to 47.1)
Other treatments exposure ongoing at baseline, n (%) (95% CI)
 NSAIDs232 (54.5) (49.6 to 59.3)307 (69.5) (64.9 to 73.7)
 Glucocorticosteroids138 (32.4) (28.0 to 37.1)152 (34.4) (30.0 to 39.0)
Line of bDMARD treatment, n (%) (95% CI)
 First line193 (45.3) (40.5 to 50.2)241 (54.5) (49.8 to 59.2)
 Second line*146 (34.3) (29.8 to 39.0)148 (33.5) (29.1 to 38.1)
 Third line*87 (20.4) (16.7 to 24.6)53 (12.0) (9.1 to 15.4)
Cardiovascular/metabolic syndrome comorbidity, n (%) (95% CI)†176 (41.3) (36.6 to 46.2)157 (35.5) (31.1 to 40.2)
  • Data are mean (SD) (95% CI of the mean) unless otherwise stated; % is that of available data. Numbers in bold indicate where significant differences exist at baseline.

  • *bDMARDs received before UST/TNFi in this study are presented in online supplemental table S2.

  • †Cardiovascular/metabolic syndrome comorbidity was numerically more frequent in the UST group.

  • bDMARD, biological disease-modifying antirheumatic drug; BMI, body mass index; csDMARD, conventional synthetic disease-modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug; TNFi, tumour necrosis factor inhibitor; UST, ustekinumab.